ライフサイエンスコーパス: pretherapy

1 enewal of clonal specificities compared with pretherapy.

2 IAFs outside the thyroid bed not detected on pretherapy ( 123)I scans in 21 (19%, P < .001) of 108 pa

3 Each patient had undergone a pretherapy ( 123)I whole-body scan followed by a postthe

4 ng occurred in 10% of patients compared with pretherapy ( 123)I whole-body scintigraphy.

5 and 114 sites and/or organs were involved on pretherapy (18)F-FDG PET and CT scans, respectively.

6 All patients underwent dual-phase pretherapy (18)F-FDG PET for which, after the intravenou

7 agnostic CT scan or on the CT component of a pretherapy (18)F-FDG PET/CT scan, whichever was obtained

8 easuring the response of patients with a low pretherapy (18)F-FDG uptake.

9 Pretherapy (60)Cu-ATSM PET provides clinically relevant

10 Methods: Data from 22 patients who underwent pretherapy (68)Ga-gallium N,N-bis[2-hydroxy-5-(carboxyet

11 Furthermore, pretherapy analysis of tumor DNA mismatch repair and, pa

12 Tumor biopsies pretherapy and 2 and 4 weeks after gene injection were o

13 CF is associated with periodontitis severity pretherapy and extent of therapeutic response post-thera

14 In this study, pretherapy and follow-up (124)I PET/CT data on BMs from

15 Pretherapy and follow-up imaging are important for stagi

16 For all lesions seen on pretherapy and midtherapy scans, the correlation was 0.9

17 The surface antigen expression profiles of pretherapy and postrelapse LSCs were determined for publ

18 nd identified 100% identical genomes between pretherapy and rebound time points.

19 tly observed in leukemic blast cells in both pretherapy and relapsed samples, consistent with MDR as

20 analysis, respectively, in biopsies from the pretherapy and surgical specimens.

21 led in the Abbott M97-720 trial at baseline (pretherapy) and weeks 60 to 384 by using an HIV-1 RNA as

22 inical attachment levels (CAL) were assessed pretherapy, and at 3 months following completion of acti

23 herapy, or rPFS for patients with or without pretherapy AR-V7-positive CTCs treated with a taxane.

24 differences in substrate specificity between pretherapy B and AE proteases.

25 Structural analysis of atazanavir bound to a pretherapy B protease showed that the ability of atazana

26 D4+ T cell counts that remained greater than pretherapy baseline levels, at least through 96 weeks of

27 decreased RXR-alpha expression compared with pretherapy bexarotene-sensitive cells.

28 Four coded sections from each of 20 pretherapy biopsies and each of 20 posttherapy biopsies

29 Pretherapy biopsy specimens were available for 265 of 50

30 Responders had lower pretherapy blasts (P =.016), a lower duration of prether

31 te neutropenia, which occurred regardless of pretherapy blood counts, and persisted an average of 2 m

32 The pretherapy blood dosimetry protocol can be substantially

33 r biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, co

34 Methods: Pretherapy blood samples from patients enrolled on a pro

35 d had a higher percentage of blasts in their pretherapy bone marrow than patients who completed 12 we

36 Pretherapy Cbl, MMA, and HCys values in individual patie

37 In these patients, pretherapy Cbl, MMA, and HCys values were normal in 54%,

38 plication and that STI was largely restoring pretherapy CD8(+) T cell responses in patients with esta

39 Disease stage was the only pretherapy clinical variable associated with outcome (P=

40 tic efficiency, 10-fold when compared to the pretherapy clone LAI.

41 Within the pretherapy cohort, 16% of patients carried low-burden TP

42 ne patients with fibrolamellar HCC underwent pretherapy computed tomography (CT); 11 underwent prethe

43 ree of response compared with dosimetry from pretherapy conjugate views alone.

44 Dosimetry based on a combination of pretherapy conjugate views and intratherapy SPECT provid

45 ompared with the same statistic estimated by pretherapy conjugate views.

46 Daily pretherapy conjugate-view images provided the shape of t

47 17 patients who had extrahepatic disease at pretherapy CT and in four of the seven patients who seem

48 istogram analysis of the primary mass on the pretherapy CT images were performed by using TexRAD soft

49 Furthermore, pretherapy CT-derived properties correlate with clinical

50 e the concept for prediction of T (eff) with pretherapy data and achieving STP shortly and flexibly a

51 mum diameter of the lesion was recorded on a pretherapy diagnostic CT scan or on the CT component of

52 l compliance exceeded 70% for structural and pretherapy disease assessment indicators but was lower f

53 patients who received chemotherapy had fewer pretherapy events than younger patients and were less li

54 itors when AR-V7-positive CTCs were detected pretherapy (hazard ratio, 0.24; 95% CI, 0.10-0.57; P = .

55 iance within the full viral coding region of pretherapy HCV sequences from 94 participants in the Vir

56 Pretherapy hepatic HCV-RNA concentrations correlated bes

57 Pretherapy HIV-1 RNA levels were prognostic independentl

58 spread, nine (29%) had distant metastases on pretherapy images, and 20 (65%) had lymphadenopathy.

59 nd between the absorbed doses predicted from pretherapy imaging and those measured after therapy (r =

60 Additional pretherapy imaging included (18)F-FDG PET/CT, CT, renal

61 cted pathologic complete response using only pretherapy imaging measures and both pre- and posttherap

62 Patients received a pretherapy imaging study with (111)In-DOTA-epratuzumab I

63 cell repertoire remodeling in the context of pretherapy immunity and ACT products.RESULTSThese analys

64 uccess was predefined as a 50% increase over pretherapy in estimated annual rate of weight gain, or c

65 ere we report that a virus, generated from a pretherapy isolate from the same patient, engineered to

66 on of the level of HIV-1 RNA did not vary by pretherapy level.

67 rs was transient when observed, returning to pretherapy levels after 28 d.

68 suppression recovered rapidly and surpassed pretherapy levels by day 7 after treatment, resulting in

69 eatment in vivo increases Akt activity above pretherapy levels within several weeks, leading to compe

70 e maintenance of plasma HIV RNA levels below pretherapy levels.

71 In these subjects, pretherapy LV SUV was markedly lower with respect to the

72 erapy computed tomography (CT); 11 underwent pretherapy magnetic resonance (MR) imaging.

73 of swallowing were only slightly worse than pretherapy measures, representing potential improvement

74 D-1 blockade in vitro and their frequency in pretherapy melanomas predicts response and survival to i

75 We analyzed pretherapy MN1 expression in 140 older (>/= 60 years) de

76 Results rR*(2,90) computed from pretherapy MRI performed 16-24 hours after FMX administr

77 Objective: To determine if pretherapy nuclear androgen-receptor splice variant 7 (A

78 ed HIV-1 RNA from viremic individuals either pretherapy or after treatment interruption, which will b

79 eal for staging patients, monitoring disease pretherapy or posttherapy, and especially for evaluating

80 of organs using machine learning applied on pretherapy patient data (PET and clinical values).

81 esentation, tumor genotype, and BRAFV600E in pretherapy peripheral blood mononuclear cells (PBMCs) an

82 The pretherapy PET data were used to segment BM volumes and

83 The pretherapy PET data were used to segment the lesion volu

84 after therapy was predicted on the basis of pretherapy PET/CT imaging and PBPK/PD modeling.

85 Pretherapy planning and posttreatment response assessmen

86 mples were identical to viral sequences from pretherapy plasma and PBMC samples, indicating that HIV-

87 herapy blasts (P =.016), a lower duration of pretherapy platelet transfusions (P =.013), and higher p

88 platelet transfusions (P =.013), and higher pretherapy platelets (P =.003).

89 The pretherapy population was composed of 22 Ta, 57 Tis, and

90 equence with significant divergence from the pretherapy population was present in either blood or lym

91 anced MRI biologic markers can be useful for pretherapy prediction of response to nal-IRI in patients

92 scriptase genotype was unrelated to outcome, pretherapy protease genotype was related significantly t

93 Pretherapy PSA, AJCC clinical stage, and biopsy Gleason

94 We demonstrate that pretherapy pulmonary function, pathologic and radiograph

95 Thirty-eight of 196 (19%) patients without pretherapy resistance evolved resistance to 1 or more dr

96 Overall, 16 of 212 (8%) patients had pretherapy resistance.

97 trained words was associated with volume of pretherapy right hemisphere white matter and post-therap

98 Initially, the assay was optimized in pretherapy samples from 20 adults with AML whose leukemi

99 Prediction analysis using pretherapy samples identified 79 genes that correctly cl

100 Pretherapy samples taken from patients that achieved CR

101 When available, pretherapy samples were also tested for t(14;18) translo

102 ntive strategies, questioning the utility of pretherapy screening computed tomography scans and masks

103 range, 0.14-1.27 Gy/GBq), whereas the median pretherapy SSTR PET renal uptake was 110.7 Bq/mL/MBq (ra

104 At each center, pretherapy SSTR PET/CT imaging and postcycle 1 (177)Lu i

105 an enlarged binding cavity when compared to pretherapy structures in the Protein Data Bank.

106 SUV were also divided into tertiles based on pretherapy SUV to investigate differences in the relativ

107 Pretherapy SUV(max) and SUV(mean) and posttherapy SUV(ma

108 There was a weak correlation with pretherapy SUVmax and Ki-67 (r = 0.29, P = 0.04), but th

109 ents, while nonresponders displayed dramatic pretherapy T cell expansions with minimal change followi

110 particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict t

111 CD4+ T cells as well as total T cells in the pretherapy TME and an increase in NK-cell CD16 and CD25

112 From pretherapy to 12 months post-therapy, the Swallowing and

113 FEV1, and FEF25-75 across the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9

114 Neither RB expression in pretherapy tumor biopsy, CTC, or tissue explants identif

115 Analysis of pretherapy tumors demonstrated that advanced primary tum

116 eep sequencing and applied this assay to 242 pretherapy tumors from patients enrolled on the phase II

117 pyuria and no alternative diagnosis) UTI on pretherapy urinalysis and culture.

118 icated cystitis, empirical therapy without a pretherapy urine culture is often used.

119 Accordingly, pretherapy urine isolates from 65 men with FUTI were com

120 reas mean CD4+ T-cell number was only 35% of pretherapy values (P < .05).

121 in lymphocytes in all patients, relative to pretherapy values.

122 ry rates in the absence of drug, relative to pretherapy VCV-sensitive isolates.

123 ART, viral diversity was not different from pretherapy viral diversity despite more than 10,000-fold

124 The level of pretherapy viremia extrapolated for each phase of decay

125 lure in the animal with the highest level of pretherapy viremia.

126 s the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versu

127 es where the posttherapy NAFX is higher than pretherapy) was even broader.

128 d annual rate of weight gain, or change from pretherapy weight loss to statistically significant on-s